[Discovery of splicing inhibitors and its impact on drug development].
Kotake
Yoshihiko
Y
yoshidam@riken.jp
Kaida
Daisuke
D
Mizui
Yoshiharu
Y
Yoshida
Minoru
M
D000818:Animals; D000970:Antineoplastic Agents; D015195:Drug Design; D004852:Epoxy Compounds / Q000494:pharmacology; D015870:Gene Expression; D006801:Humans; D007438:Introns; D018942:Macrolides / Q000494:pharmacology; D011714:Pyrans / Q000494:pharmacology; D012323:RNA Processing, Post-Transcriptional; D012326:RNA Splicing / Q000187:drug effects / Q000235:genetics; D000072260:RNA Splicing Factors; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D016601:RNA-Binding Proteins; D017413:Ribonucleoprotein, U2 Small Nuclear; D013141:Spiro Compounds / Q000494:pharmacology; D017381:Spliceosomes
D000970:Antineoplastic Agents; D004852:Epoxy Compounds; C104486:FR 901464; D018942:Macrolides; D011714:Pyrans; D000072260:RNA Splicing Factors; D012333:RNA, Messenger; D016601:RNA-Binding Proteins; D017413:Ribonucleoprotein, U2 Small Nuclear; C486349:SF3B3 protein, human; D013141:Spiro Compounds; C522342:pladienolide B